share_log

Novavax | SC 13D: Statement of acquisition of beneficial ownership by individuals-Himanshu H. Shah(6.70%),Shah Capital Management(6.66%), etc.

Novavax | SC 13D: Statement of acquisition of beneficial ownership by individuals

諾瓦瓦克斯醫藥 | SC 13D:超過5%持股股東披露文件
美股sec公告 ·  04/15 06:28
Moomoo AI 已提取核心訊息
On April 10, 2024, Shah Capital Management, Inc., Shah Capital Opportunity Fund LP, and Himanshu H. Shah, collectively referred to as the Reporting Persons, filed a Schedule 13D with the United States Securities and Exchange Commission (SEC) regarding their significant investment in Novavax, Inc. The filing indicates that Shah Capital Management, as an investment adviser, and Shah Capital Opportunity Fund LP, a partnership, along with Himanshu H. Shah, President and Chief Investment Officer of Shah Capital, have acquired substantial shares of Novavax. The Reporting Persons collectively own 9,326,176 shares through Shah Capital Management, 8,700,000 shares through Shah Capital Opportunity Fund LP, and 9,383,335 shares by Himanshu H. Shah individually, representing 6.66%, 6.21%, and 6.70% of the outstanding shares, respectively. The shares were acquired for investment purposes in the ordinary...Show More
On April 10, 2024, Shah Capital Management, Inc., Shah Capital Opportunity Fund LP, and Himanshu H. Shah, collectively referred to as the Reporting Persons, filed a Schedule 13D with the United States Securities and Exchange Commission (SEC) regarding their significant investment in Novavax, Inc. The filing indicates that Shah Capital Management, as an investment adviser, and Shah Capital Opportunity Fund LP, a partnership, along with Himanshu H. Shah, President and Chief Investment Officer of Shah Capital, have acquired substantial shares of Novavax. The Reporting Persons collectively own 9,326,176 shares through Shah Capital Management, 8,700,000 shares through Shah Capital Opportunity Fund LP, and 9,383,335 shares by Himanshu H. Shah individually, representing 6.66%, 6.21%, and 6.70% of the outstanding shares, respectively. The shares were acquired for investment purposes in the ordinary course of business, with no current plans to influence or change the company's operations. The Reporting Persons may engage in discussions with Novavax's management or other stakeholders and may alter their investment strategy based on the company's performance and market conditions. The filing also includes a Joint Filing Agreement and a letter to the Board of Directors (BOD Letter) as exhibits.
2024年4月10日,Shah Capital Management, Inc.、Shah Capital Opportunity Fund LP和Himanshu H. Shah(統稱爲申報人)就其對Novavax, Inc.的重大投資向美國證券交易委員會(SEC)提交了附表13D。該文件顯示,作爲投資顧問的沙阿資本管理公司和合夥企業Shah Capital Opportunity Fund LP以及總裁兼首席Himanshu H. Shah Shah Capital的投資官已經收購了Novavax的大量股份。申報人通過Shah資本管理公司共擁有9,326,176股股票,通過Shah Cap...展開全部
2024年4月10日,Shah Capital Management, Inc.、Shah Capital Opportunity Fund LP和Himanshu H. Shah(統稱爲申報人)就其對Novavax, Inc.的重大投資向美國證券交易委員會(SEC)提交了附表13D。該文件顯示,作爲投資顧問的沙阿資本管理公司和合夥企業Shah Capital Opportunity Fund LP以及總裁兼首席Himanshu H. Shah Shah Capital的投資官已經收購了Novavax的大量股份。申報人通過Shah資本管理公司共擁有9,326,176股股票,通過Shah Capital Opportunity Fund LP共擁有8,700,000股股票,Himanshu H. Shah單獨擁有9,383,335股股票,分別佔已發行股份的6.66%、6.21%和6.70%。這些股票是在正常業務過程中出於投資目的而收購的,目前沒有影響或改變公司運營的計劃。申報人可以與Novavax的管理層或其他利益相關者進行討論,並可能根據公司的業績和市場狀況改變其投資策略。該文件還包括一份聯合申報協議和一封致董事會的信函(BOD 信函)作爲證物。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息